Grail’s Galleri Misses Primary Endpoint in NHS Trial, FDA Review Now In Focus

 
• By Shubham Singh
  
The Galleri test also showed enhanced Stage I/II identification for aggressive cancers lacking routine screens, alongside an average time to diagnosis of 46 days and low false positives (0.4%). Picture Courtesy: Shutterstock

More from Oncology

More from Device Area